Skip to search formSkip to main contentSkip to account menu

MDX-010

Known as: MDX 010, MDX-101, MDX010 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

ipilimumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Safety and efficacy of ipilimumab in melanoma patients who received prior immunotherapy on phase III study MDX010-020.
9050 Background: MDX010-020 was a phase III comparison of ipilimumab (Ipi), gp100 vaccine or the combination for advanced… 
2011
2011
18F-FDG PET/CT imaging of an anti-CTLA-4 antibody-associated autoimmune pancolitis
Review
2011
Review
2011
Overall survival (OS) in the management of pretreated patients with unresectable stage III/IV melanoma: A systematic literature review and meta-analysis.
8580 Background: Ipilimumab is the first treatment to show an OS benefit in a phase III trial (MDX010-20) compared with a gp100… 
Review
2009
Review
2009
The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer management
Background: Cytotoxic T lymphocyte antigen 4 (CTLA-4) is an inhibitory regulator of the T cell immune response against tumor… 
2009
2009
Down-staging of locally advanced prostate cancer with anti-CTLA-4 monoclonal antibody prior to radical prostatectomy.
e16103 Background: At present, androgen ablation (AA) therapy ± radiation therapy represents a first-line treatment for patients… 
2007
2007
7005 ORAL Ipilimumab (MDX-010) in patients with stage III/IV melanoma: kinetics and duration of response
2006
2006
Is tumor immunity the same thing as autoimmunity? Implications for cancer immunotherapy.
The immune system is capable of inducing tumor regression in selected patients, and the mechanisms regulating this process are… 
2006
2006
Phase I/II Study of Ipilimumab (MDX-010), an Anti-CTLA-4 Monoclonal Antibody, in Patients with Follicular Non-Hodgkin Lymphoma.
Background: Follicular lymphoma is a B-cell malignancy in which tumor-immune system interactions have the potential to profoundly… 
2004
2004
A phase II, randomized multi-center study of MDX-010 alone or in combination with dacarbazine (DTIC) in stage IV metastatic malignant melanoma.
7511 Background: MDX-010 is a human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 and augments immune responses. In… 
2004
2004
Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody blockade in patients previously vaccinated with irradiated, autologous tumor cells engineered to secrete granulocyte-macrophage colony…
2536 Background: Vaccination with irradiated, autologous tumor cells engineered to secrete GM-CSF (GVAX) consistently stimulates… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)